Welcome to our dedicated page for Zura Bio SEC filings (Ticker: ZURA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Zura Bio Limited (Nasdaq: ZURA) SEC filings page on Stock Titan provides centralized access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a clinical-stage, multi-asset immunology company developing novel antibodies for autoimmune and inflammatory diseases, Zura Bio uses its SEC filings to report on financial performance, risk factors, governance matters, and material corporate events.
Through periodic reports such as the Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, Zura Bio presents audited and unaudited financial statements, details on research and development expenses, general and administrative costs, cash and cash equivalents, and net losses. These filings also describe the company’s pipeline, including tibulizumab (ZB-106), crebankitug (ZB-168), and torudokimab (ZB-880), and outline key risks associated with its clinical-stage status and lack of approved products.
Current reports on Form 8-K document specific material events, such as leadership transitions, executive appointments, adoption of executive severance plans, financial result announcements, and updates to corporate presentations. For example, Zura Bio has filed 8-Ks regarding changes in its chief executive officer and chief financial officer roles, the launch of investor presentations, and the release of quarterly financial results.
On Stock Titan, these filings are supplemented by AI-powered summaries that aim to explain the main points of lengthy documents, helping readers quickly identify items such as cash runway disclosures, clinical program descriptions, or changes in executive compensation arrangements. Users can also review exhibits referenced in 8-Ks, including press releases and key agreements, where available.
This page is useful for investors and researchers who want to analyze Zura Bio’s official regulatory record, track how its immunology programs are described in formal filings, and monitor governance and compensation developments over time, all with real-time updates sourced from the SEC’s EDGAR system.
Deep Track Capital, Deep Track Biotechnology Master Fund and David Kroin report a collective stake of 4,616,514 Class A Ordinary Shares in ZURA Bio Ltd, representing 7.13% of the class. The filing shows the reporting persons hold shared voting and shared dispositive power for all 4,616,514 shares and no sole voting or dispositive power. The ownership calculation uses a share base of 64,763,950, which combines 61,874,998 outstanding ordinary shares and 2,882,952 pre-funded warrants that the reporting persons could convert subject to a 9.99% maximum exercise limitation. The filing includes a certification that the securities were not acquired to change or influence control of the issuer.
Zura Bio Limited reported advancing clinical programs while continuing to operate at a loss. As of June 30, 2025 the company held $154.5 million in cash and cash equivalents and reported a net loss of $15.993 million for the three months ended June 30, 2025 and $33.435 million for the six months ended June 30, 2025, leaving an accumulated deficit of $189.3 million. The balance sheet shows total assets of $157.8 million and total shareholders' equity of $127.4 million.
The company is a clinical-stage immunology company developing tibulizumab (ZB-106), which entered a global Phase 2 study TibuSHIELD in May 2025 (~180 adults) and previously initiated TibuSURE (Dec 2024, ~80 participants). Zura also lists two other clinical assets, crebankitug and torudokimab. The filing discloses contingent milestone and royalty obligations under multiple license agreements and a pending $5.0 million invoice related to a finder’s fee that the company is reviewing. Management states it expects existing liquidity to fund operations for the next twelve months.
Zura Bio Limited furnished a press release announcing its second quarter 2025 financial results and attached that press release as Exhibit 99.1 to this Form 8-K. The filing states the results disclosure is furnished under Item 2.02 rather than "filed," and the press release itself is incorporated by reference into the exhibit list.
The company also confirms its securities trading symbol and that it qualifies as an emerging growth company. No financial tables, specific revenue, earnings or other numeric results are included within the 8-K text; interested readers must refer to Exhibit 99.1 for the full press release content.
Zura Bio Limited (Nasdaq: ZURA) filed an 8-K announcing a leadership transition in its finance organization. The Board has appointed Eric Hyllengren as Chief Financial Officer, effective July 7, 2025. Hyllengren brings more than two decades of biotech experience, most recently serving as CFO/COO of Atara Biotherapeutics and holding multiple senior finance roles at Amgen. His compensation package includes a $475,000 base salary, a target bonus equal to 40 % of salary, and an inducement option for 672,000 Class A shares that vests over four years.
Current CFO Verender Badial tendered his resignation on June 25, 2025. He will stay through the effective date and remain as a non-executive employee until July 31, 2025 to ensure continuity. A Settlement Agreement provides Badial with cash severance and benefits totaling roughly £295,000, accelerated vesting on options covering 186,561 shares, transfer restrictions on those shares for up to three years, and an extension of option exercise periods. Options for 303,100 shares granted on May 8, 2025 will be forfeited.
Key implications for investors:
- The company gains an experienced biotech finance executive with M&A, operations and capital-markets expertise.
- Management states the transition is not related to accounting disagreements, reducing concern over financial reporting integrity.
- Severance and inducement equity create modest near-term cash outflow and long-term dilution, but no immediate impact on operating results.
A press release dated July 1, 2025 regarding these changes was furnished as Exhibit 99.1.